ストックスクリーナーアプリを入手
30.38
0.73%
0.22
アフターアワーズ：
30.12
-0.26
-0.86%
Eton Pharmaceuticals Inc (ETON) 最新ニュース
Eton Pharmaceuticals (ETON) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Eton Scales New Highs On Sustained Growth Momentum - RTTNews
Eton Pharmaceuticals (ETON) surges 19.8%: Is this an indication of further gains? - MSN
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 - The Manila Times
Eton Pharmaceuticals sets May 14 earnings report, webcast at 4:30 p.m. ET - Stock Titan
Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains? - Yahoo Finance
How The Hemangeol Deal Is Rewriting The Story For Eton Pharmaceuticals (ETON) - Yahoo Finance
Eton Pharmaceuticals Touches New High Amid Relaunch of Hemangeol - Moomoo
Eton Pharmaceuticals (NASDAQ:ETON) Reaches New 12-Month HighTime to Buy? - MarketBeat
Eton Pharmaceuticals (NASDAQ:ETON) Trading 13.3% HigherWhat's Next? - MarketBeat
Eton Pharmaceuticals Relaunches HEMANGEOL With Exclusive Distribution - TipRanks
Eton Pharmaceuticals relaunches Hemangeol with specialty pharmacy By Investing.com - Investing.com Australia
Eton Pharmaceuticals, Inc. (ETON) announced that its product Hemangeol® (propranolol) oral solution has been officially relaunched. - Bitget
Eton Pharmaceuticals relaunches Hemangeol with specialty pharmacy - Investing.com
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution - The Manila Times
Eton Pharmaceuticals Announces Exclusive Launch of HEMANGEOL Through Anovo Specialty Pharmacy to Enhance Patient Access and Support for Infantile Hemangioma Treatment - Quiver Quantitative
Only FDA-approved infantile hemangioma drug returns with $0 copay - Stock Titan
Does Eton Pharmaceuticals (ETON) have the potential to rally 49.25% as Wall Street analysts expect? - MSN
Eton Pharmaceuticals (ETON) soars 6.7%: Is further upside left in the stock? - MSN
Eton Pharma drops after CFO succession plan - MSN
Recent price trend in Eton Pharmaceuticals (ETON) is your friend, here's why - MSN
Eton Pharmaceuticals Initiates Clinical Study for ET-700 Zinc Acetate Extended-Release Formulation for Wilson Disease - Minichart
Eton Starts Pilot Trial of ET-700 for Wilson Disease - TipRanks
Eton Pharmaceuticals doses first patient in Wilson disease study By Investing.com - Investing.com Australia
Eton Pharmaceuticals doses first patient in Wilson disease study - Investing.com
Eton Pharmaceuticals Announces First Patient Dosed in Pilot Study for ET-700 in Wilson Disease Treatment - Quiver Quantitative
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700 - The Manila Times
Eton Pharmaceuticals Initiates Clinical Study For Product Candidate ET-700 - marketscreener.com
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of "Hold" by Brokerages - MarketBeat
(ETON) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Eton Pharmaceuticals (ETON) price target increased by 25.56% to 38.42 - MSN
Eton Pharmaceuticals (ETON) 2026 proxy outlines director votes and 2025 CEO pay - Stock Titan
Eton Pharmaceuticals (ETON) Appoints Judith M. Matthews as New CFO - Insider Monkey
10 Best NASDAQ Growth Stocks to Buy and Hold Forever - Insider Monkey
Eton Pharmaceuticals sees its composite rating rise to 97 - MSN
The Escalator: Pfizer, Eton Pharmaceuticals, Steak ‘n Shake and more - Medical Marketing and Media
ETON (Eton Pharmaceuticals Inc.) posts wide Q4 2025 EPS miss, shares edge lower on underwhelming quarterly results.Professional Trade Ideas - Xã Thanh Hà
Eton director exercises options for 32,155 shares | ETON Insider Trading - Stock Titan
Eton Pharmaceuticals (NASDAQ:ETON) Shares Down 6%Should You Sell? - MarketBeat
0.67%
2.13%
大文字化:
|
ボリューム (24 時間):